Page 4 - Radcom News Today

The U.S. FDA’s Pulmonary-Allergy Drugs Advisory Committee has a lot to discuss Nov. 17, but only one voting question: Does the evidence demonstrate that Merck & Co. Inc.’s gefapixant provides a clinically meaningful benefit to adults with refractory or unexplained chronic cough?

Dime Community Bancshares (NASDAQ:DCOM – Get Free Report) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Monday. Separately, Raymond James reduced their price target on Dime Community Bancshares from $27.00 to $23.00 and set an “outperform” rating for the company in a […]

Had it been asked to, the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee would have voted Oct. 31 to recommend approval of Vertex Pharmaceutical Inc. and Crispr Therapeutics AG’s exagamglogene autotemcel, or exa-cel, as a one-time transformative treatment for severe sickle cell disease in individuals 12 and older.

StockNews.com began coverage on shares of RADCOM (NASDAQ:RDCM – Free Report) in a report released on Monday. The brokerage issued a buy rating on the technology company’s stock. RADCOM Stock Performance NASDAQ:RDCM opened at $7.99 on Monday. The stock has a 50-day simple moving average of $8.67 and a two-hundred day simple moving average of […]

Brown Advisory Inc. lessened its holdings in shares of Dime Community Bancshares, Inc. (NASDAQ:DCOM – Free Report) by 7.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 692,086 shares of the savings and loans company’s stock after selling 52,635 shares during the period. […]

StockNews.com assumed coverage on shares of RADCOM (NASDAQ:RDCM – Free Report) in a research note issued to investors on Sunday. The firm issued a buy rating on the technology company’s stock. RADCOM Trading Up 0.7 % NASDAQ:RDCM opened at $8.43 on Friday. The firm has a market cap of $124.26 million, a PE ratio of […]

RADCOM Ltd. (NASDAQ:RDCM – Get Free Report) was the target of a significant drop in short interest in September. As of September 30th, there was short interest totalling 11,300 shares, a drop of 26.1% from the September 15th total of 15,300 shares. Based on an average daily volume of 7,900 shares, the days-to-cover ratio is […]

StockNews.com assumed coverage on shares of RADCOM (NASDAQ:RDCM – Free Report) in a research report report published on Saturday morning. The brokerage issued a buy rating on the technology company’s stock. RADCOM Stock Performance Shares of NASDAQ:RDCM opened at $8.21 on Friday. RADCOM has a 52-week low of $8.21 and a 52-week high of $11.50. […]

StockNews.com initiated coverage on shares of Dime Community Bancshares (NASDAQ:DCOM – Free Report) in a research report report published on Thursday. The brokerage issued a hold rating on the savings and loans company’s stock. Separately, Raymond James lifted their target price on Dime Community Bancshares from $23.00 to $27.00 and gave the stock an outperform […]

The dark cloud of what the U.S. FDA called potential “systemic bias” rained on Amgen Inc.’s bid for full approval of Lumakras (sotorasib), a KRAS-G12C inhibitor that was granted accelerated approval in May 2021 for locally advanced or metastatic non-small-cell lung cancer after at least one systemic therapy.